CASTRES, Frankreich, 28. Juni 2024 /PRNewswire/ — Die Europäische Kommission (EK) hat die Vermarktung von OBGEMSA™ (Vibegron) von Pierre Fabre Laboratories zur symptomatischen Behandlung des überaktiven Blasensyndroms bei Erwachsenen genehmigt, einer besonders schwächenden Erkrankung,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.